P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease

P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma.

Click here to read the entire release.

About The Author

Kevin Wilson

Other posts by

Author his web site

19

07 2011

Comments are closed.